Literature DB >> 11086173

Continuous hematopoietic cell lines as model systems for leukemia-lymphoma research.

H G Drexler1, A Y Matsuo, R A MacLeod.   

Abstract

Along with other improvements, the advent of continuous human leukemia-lymphoma (LL) cell lines as a rich resource of abundant, accessible and manipulable living cells has contributed significantly to a better understanding of the pathophysiology of hematopoietic tumors. The first LL cell lines, Burkitt's lymphoma-derived lines, were established in 1963. Since then, more than 1000 cell lines have been described, although not all of them in full detail. The major advantages of continuous cell lines is the unlimited supply and worldwide availability of identical cell material, and the infinite viable storability in liquid nitrogen. LL cell lines are characterized generally by monoclonal origin and differentiation arrest, sustained proliferation in vitro under preservation of most cellular features, and specific genetic alterations. The most practical classification of LL cell lines assigns them to one of the physiologically occurring cell lineages, based on their immunophenotype, genotype and functional features. Truly malignant cell lines must be discerned from Epstein-Barr virus (EBV)-immortalized normal cells, using various distinguishing parameters. However, the picture is not quite so straightforward, as some types of LL cell lines are indeed EBV+, and some EBV+ normal cell lines carry also genetic aberrations and may mimic malignancy-associated features. Apart from EBV and human T-cell leukemia virus in some lines, the majority of wild-type LL cell lines are virus-negative. The efficiency of cell line establishment is rather low and the deliberate establishment of new LL cell lines remains by and large an unpredictable random process. Difficulties in establishing continuous cell lines may be caused by the inappropriate selection of nutrients and growth factors for these cells. Clearly, a generally suitable microenvironment for hematopoietic cells, either malignant or normal, cannot yet be created in vitro. The characterization and publication of new LL cell lines should provide important and informative core data, attesting to their scientific significance. Large percentages of LL cell lines are contaminated with mycoplasma (about 30%) or are cross-contaminated with other cell lines (about 15-20%). Solutions to these problems are sensitive detection, effective elimination and rigorous prevention of mycoplasma infection, and proper, regular authentication of cell lines. The underlying cause, however, appears to be negligent cell culture practice. The willingness of investigators to make their LL cell lines available to others is all too often limited. There is a need in the scientific community for clean and authenticated high-quality LL cell lines to which every scientist has access. These are offered by various institutionalized public cell line banks. It has been argued that LL cell lines are genetically unstable (both cytogenetically and molecular genetically). For instance, cell lines are supposed to acquire numerical and structural chromosomal alterations and various types of mutations (e.g. point mutations) in vitro. We present evidence that while nearly 100% of all LL cell lines indeed carry genetic alterations, these alterations appear to be stable rather than unstable. As an example of the practical utility of LL cell lines, the recent advances in studies of classical and molecular cytogenetics, which in large part were made possible by cell lines, are highlighted. A list of the most useful, robust and publicly available reference cell lines that may be used for a variety of experimental purposes is proposed. Clearly, by opening new avenues for investigation, studies of LL cell lines have provided seminal insights into the biology of hematopoietic neoplasia. Over a period of nearly four decades, these initially rather exotic cell cultures, known only to a few specialists, have become ubiquitous powerful research tools that are available to every investigator.

Entities:  

Mesh:

Year:  2000        PMID: 11086173     DOI: 10.1016/s0145-2126(00)00070-9

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  12 in total

1.  Quality of Cell Products: Authenticity, Identity, Genomic Stability and Status of Differentiation.

Authors:  Kurt E J Dittmar; Meike Simann; Nadia Zghoul; Oliver Schön; Wilhelm Meyring; Horst Hannig; Lars Macke; Wilhelm G Dirks; Konstantin Miller; Henk S P Garritsen; Werner Lindenmaier
Journal:  Transfus Med Hemother       Date:  2010-03-08       Impact factor: 3.747

Review 2.  Reappraisal of BCL3 as a molecular marker of anaplastic large cell lymphoma.

Authors:  Hitoshi Ohno; Momoko Nishikori; Yoshitomo Maesako; Hironori Haga
Journal:  Int J Hematol       Date:  2005-12       Impact factor: 2.490

3.  Identification of genes deregulated during serum-free medium adaptation of a Burkitt's lymphoma cell line.

Authors:  L Zander; M Bemark
Journal:  Cell Prolif       Date:  2008-02       Impact factor: 6.831

4.  APC2 and Axin promote mitotic fidelity by facilitating centrosome separation and cytoskeletal regulation.

Authors:  John S Poulton; Frank W Mu; David M Roberts; Mark Peifer
Journal:  Development       Date:  2013-09-11       Impact factor: 6.868

5.  Use of transcriptional signatures induced in lymphoid and myeloid cell lines as an inflammatory biomarker in Type 1 diabetes.

Authors:  Shuang Jia; Mary Kaldunski; Parthav Jailwala; Rhonda Geoffrey; Joanna Kramer; Xujing Wang; Martin J Hessner
Journal:  Physiol Genomics       Date:  2011-03-15       Impact factor: 3.107

6.  Establishment of transplantable porcine tumor cell lines derived from MHC-inbred miniature swine.

Authors:  Patricia S Cho; Diana P Lo; Krzysztof J Wikiel; Haley C Rowland; Rebecca C Coburn; Isabel M McMorrow; Jennifer G Goodrich; J Scott Arn; Robert A Billiter; Stuart L Houser; Akira Shimizu; Yong-Guang Yang; David H Sachs; Christene A Huang
Journal:  Blood       Date:  2007-08-16       Impact factor: 22.113

7.  Transcription factor expression in cell lines derived from natural killer-cell and natural killer-like T-cell leukemia-lymphoma.

Authors:  Yoshinobu Matsuo; Hans G Drexler; Akira Harashima; Ayumi Okochi; Norio Shimizu; Kunzo Orita
Journal:  Hum Cell       Date:  2004-06       Impact factor: 4.174

8.  Establishment of a novel human lymphoblastic cell strain with the long arm of chromosome 11 aberration without MLL rearrangement.

Authors:  Qian Wang; Lin Zhuang; Pei Li; Qiang Niu; Ping Zhu; Miao-Xia He; Hui Jiang; Chang-Cheng Liu; Min-Jun Wang; Li Chen; Hui Cheng; Yan Ma; Xiao-Xia Hu; Yi-Ping Hu; Xiao-Ping Xu
Journal:  Sci Rep       Date:  2017-04-13       Impact factor: 4.379

9.  Comprehensive genomic characterization of five canine lymphoid tumor cell lines.

Authors:  Sarah C Roode; Daniel Rotroff; Kristy L Richards; Peter Moore; Alison Motsinger-Reif; Yasuhiko Okamura; Takuya Mizuno; Hajime Tsujimoto; Steven E Suter; Matthew Breen
Journal:  BMC Vet Res       Date:  2016-09-17       Impact factor: 2.741

10.  VR09 cell line: an EBV-positive lymphoblastoid cell line with in vivo characteristics of diffuse large B cell lymphoma of activated B-cell type.

Authors:  Ilaria Nichele; Alberto Zamò; Anna Bertolaso; Francesco Bifari; Martina Tinelli; Marta Franchini; Roberta Stradoni; Fiorenza Aprili; Giovanni Pizzolo; Mauro Krampera
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.